Latest Global Markets News

1414 Degrees has raised $2.69 million to accelerate its clean energy storage technologies, targeting the booming global data centre market and industrial energy users.

Coppermoly Limited has expanded its Australian footprint by acquiring the Wyemandoo Project in Western Australia, adding high-grade critical minerals to its portfolio. The acquisition enhances exploration potential across a combined 1,805 square kilometres in WA and Queensland.

Alpha HPA Limited reports a surge in semiconductor sector demand driven by AI infrastructure expansion, with significant upgrades in Letters of Intent from key Japanese customers and ongoing capacity expansion.

4DMedical’s advanced lung imaging technology CT:VQ™ has been deployed at the Mayo Clinic, marking the sixth top US academic medical centre to adopt the system within seven months of FDA clearance.

Klevo Rewards partners with Bybit to launch KLVAUD, an Australian dollar-backed stablecoin integrated with a Mastercard and a global rewards ecosystem. This move aims to transform everyday spending into digital asset rewards accessible worldwide.

VHM Ltd has secured board approval to develop its Goschen Rare Earths and Mineral Sands Project at full capacity, signalling a strategic pivot to meet surging global demand for critical minerals.

The Speewah Fluorite Project in Western Australia has been officially recognised by the Japanese and US governments as a critical minerals supply chain asset, signalling strong international support and potential financial backing.

WA Kaolin Limited has announced a $34.9 million recapitalisation plan involving a non-renounceable entitlement issue and debt conversion to strengthen its balance sheet and fund operational improvements at its Wickepin kaolin project.

The Australian Government has increased financial support thresholds for Viva Energy’s Geelong Refinery, reflecting rising operating costs and reinforcing domestic fuel security through the decade.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Tivan Limited’s joint venture partners have approved the Feasibility Study for the Speewah Fluorite Project and committed a $5 million equity injection to advance development.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.